Actively Recruiting
Open Label Study of QRX003 Lotion in People With Netherton Syndrome Evaluating Safety and Effectiveness
Led by Quoin Pharmaceuticals · Updated on 2026-08-31
20
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating QRX003 lotion 4% as an addition to standard care, including systemic therapy, in people with Netherton syndrome. The study aims to assess the safety, tolerability, and effectiveness of this topical treatment over a 12-week period. This open-label trial involves participants who have a confirmed clinical diagnosis of Netherton syndrome and lesions on their arms or lower legs. Participants will apply QRX003 lotion once or twice daily for 12 weeks. Two treatment groups will compare once-daily morning application to twice-daily application. The lotion contains a 4% active serine protease inhibitor. The study is designed as a single-group, non-randomized trial with no placebo or blinding involved. During the study, participants will be monitored for changes in skin condition using measures such as Investigator Global Assessment IGA scores, affected skin surface area, and itch severity WI-NRS. Subject satisfaction with treatment and the need for rescue therapy will also be assessed. Safety will be closely monitored through reports of adverse events and local skin reactions. The total participation duration is up to 16 weeks, including treatment and follow-up assessments.
CONDITIONS
Brief Title
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Research Team
T
TI Clinical Research
O
Oleg G Khatsenko
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here